Sarepta Therapeutics (SRPT) Misses Q1 EPS by 457c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($5.86), $4.57 worse than the analyst estimate of ($1.29). Revenue for the quarter came in at $253.5 million versus the consensus estimate of $242.4 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
• Tutor Perini launches $400M senior notes offering due 2033